REDONDO BEACH, CA--(Marketwired - Dec 14, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing recent additions to AXIM Biotechnologies' (OTCQB: AXIM) Advisory Board, as well as the overall impact the seasoned team of executives and advisors has on the company moving forward.

AXIM Biotech, a world leader in cannabinoid research and development, recently announced the addition of Dr. Ilya Reznik to its Advisory Board. As a Board-certified specialist in Adult Forensic and Clinical Neuro Psychiatry at the MaReNa Diagnostic and Consulting Center in Israel and a clinical practitioner utilizing medical cannabis in patient treatment for years, Dr. Reznik will be an invaluable asset to the company.

AXIM is developing a broad portfolio of therapeutics leveraging its innovative delivery systems. Among these programs, the company is contemplating the treatment of drug-related and early psychosis with its AX-1604. The company expects to complete a POC Phase IIA clinical trial in 2018 and a Phase III clinical trial by 2020 with a projected NDA in 2021, according to its product pipeline.

Dr. Ilya Reznik is a top psychiatry specialist with extensive clinical experience treating patients with medical cannabis. He has also published original research papers -- including controlled trials -- in peer-reviewed journals in the fields of clinical psychiatry and neuropsychopharmacology. With this background, his expertise could prove invaluable in bringing AX-1604 through clinical trials over the coming years.

AXIM Biotech's strategy of recruiting industry experts isn't limited to psychosis. With nine members of its advisory board, the company has cultivated expertise across medical fields ranging from multiple sclerosis to glaucoma. These experts will be instrumental in supporting the company's clinical programs as they advance from pre-clinical and Phase I trials to Phase IIA clinical trials that could generate significant value for investors.

For example, Professor John Zajicek is the Chair in Medicine at the University of St. Andrews School of Medicine and holds a Ph.D. in cell biology of myelination in Cambridge. As a former Chief Investigator in several large multi-center randomized controlled trials, including the investigation of cannabinoid use in multiple sclerosis, Dr. Zajicek will be instrumental in advancing the company's neurodegeneration programs through clinical trials.

Dr. Murad Sunalp is another example of a well-respected advisory board member that is an ophthalmologist and entrepreneur that trained at Oxford and Stanford. With more than 20,000 cataract surgeries and 5,000 LASIK surgeries performed, he is a well-regarded expert in areas like glaucoma and could be instrumental in helping the company advance its AX-1603 program through clinical trials and eventual regulatory approval.

Follow the link to read the full article:


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information:
Paul Archie